Dr. Callahan and Dr. Bardia discuss DESTINY-Breast04 and DESTINY-Breast06, studies that have significantly broadened the use of T-DXd into HER2-low and ultra-low populations, redefining patient eligibility and what was once thought “non-curable”.
Topics Covered:
• DESTINY-Breast04 and 06 trial outcomes
• Clinical implications of broader HER2 targeting
• Importance of accurate HER2 testing
DESTINY-Breast Trials: Expanding Treatment Horizons
You may also like
Recommended Videos
